Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-05-27 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT' and covers the period 'January - March 2025'. It contains comprehensive financial statements, including an income statement, report on financial position, cash flow, and notes, as well as management commentary. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2025
2025-05-27 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding ('Innehavare', 'Transaktionen: Köp') by a major shareholder ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension') in SynAct Pharma AB. It specifies the number of shares held before and after the transaction, the resulting percentage ownership (10.23702%), and the date of the transaction (2025-05-21). This structure is characteristic of a Major Shareholding Notification, where an entity reports crossing a threshold of ownership (here, crossing 10%). This aligns directly with the definition for Major Shareholding Notification (Code: MRQ).
2025-05-22 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage ('Innehavare' section) for a specific instrument ('Aktier') by an entity ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension'). Key indicators are the transaction type ('Sälj' - Sell), the resulting share count (4,845,981), and the resulting percentage ownership (9.88796%), which crosses or is near a threshold (10%). This structure is characteristic of a notification regarding a significant change in major share ownership, often mandated by financial regulators (implied by the reference to 'LHF' and 'FI' in the footnotes, suggesting a Swedish regulatory context). This aligns precisely with the definition of Major Shareholding Notification (MRQ).
2025-05-20 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding ('Köp' - Purchase) by an entity (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in SynAct Pharma AB, crossing a threshold ('Gränsvärde för antal aktier' is 10%). It explicitly reports the 'Andel' (Share) before and after the transaction, including the total number of shares and voting rights. This structure is characteristic of a Major Shareholding Notification, where an investor reports crossing ownership thresholds as required by financial regulations (implied by the reference to 'LHF' and 'FI' - likely the Swedish Financial Supervisory Authority). This matches the definition for Major Shareholding Notification (MRQ).
2025-05-15 Swedish
Notice of annual general meeting in SynAct Pharma AB
AGM Information Classification · 99% confidence The document is explicitly titled "Notice of annual general meeting in SynAct Pharma AB" and details the date, time, location, registration procedures, proposed agenda items (including election of Chairman, approval of financial statements, remuneration, and board elections), and specific proposals related to these items. This content is the core material distributed to shareholders in advance of an Annual General Meeting (AGM) to inform their voting decisions. This aligns perfectly with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. Although it mentions the annual report (Item 8), the document itself is the notice and proxy material, not the full 10-K or the standalone Audit Report (AR). It is not a Report Publication Announcement (RPA) because it contains the substantive details of the meeting and proposals, rather than just announcing that a report is available.
2025-04-24 English
Kallelse till årsstämma i SynAct Pharma AB
AGM Information Classification · 99% confidence The document is titled "Kallelse till årsstämma i SynAct Pharma AB" (Notice of Annual General Meeting in SynAct Pharma AB). It details the date, time, location, registration requirements, agenda items (including election of board members, approval of financial statements, and remuneration guidelines), and proposals to be voted upon at the meeting. This content is characteristic of a formal notice calling shareholders to an Annual General Meeting (AGM). The specific code for AGM materials is AGM-R.
2025-04-24 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.